| 1 |
34199712 | Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites. | 2021 Jun 4 |
1 |
| 2 |
31785970 | Cytochrome P450 2C9 polymorphism: Effect of amino acid substitutions on protein flexibility in the presence of tamoxifen. | 2020 Feb |
10 |
| 3 |
27198207 | Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. | 2016 Dec |
1 |
| 4 |
25618289 | Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. | 2015 Mar |
1 |
| 5 |
25940823 | Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. | 2015 Aug |
1 |
| 6 |
23604525 | Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies. | 2013 Jun |
1 |
| 7 |
21480951 | Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. | 2011 May |
1 |
| 8 |
21906462 | The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. | 2011 Sep |
1 |
| 9 |
21152245 | Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. | 2010 |
1 |
| 10 |
19843839 | Safety of concomitant tamoxifen and warfarin. | 2009 Nov |
1 |
| 11 |
17024799 | Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. | 2006 Aug |
6 |
| 12 |
14642736 | Biotransformation of tamoxifen in a human endometrial explant culture model. | 2003 Dec 15 |
2 |
| 13 |
14678248 | Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies. | 2003 Nov |
1 |
| 14 |
12207635 | The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. | 2002 Aug |
1 |
| 15 |
8681455 | The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: potential importance to its proposed anti-carcinogenic/carcinogenic actions. | 1996 Jun |
1 |